$WTMA
Welsbach Technology Metals Acquisition Corp

2023 Q2 Form 10-Q Financial Statement

#000121390023039750 Filed on May 15, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $380.6K $908.3K $577.1K
YoY Change 21.61% 57.4%
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $380.6K $908.3K $577.1K
YoY Change 21.61% 57.41%
Operating Profit -$908.3K
YoY Change
Interest Expense $502.1K $845.1K $7.780K
YoY Change 381.18% 10762.34%
% of Operating Profit
Other Income/Expense, Net $502.1K $845.1K $7.777K
YoY Change 381.19% 10766.53%
Pretax Income $121.5K -$63.23K -$569.3K
YoY Change -158.22% -88.89%
Income Tax $94.94K $167.0K
% Of Pretax Income 78.16%
Net Earnings $26.53K -$230.2K -$569.3K
YoY Change -112.71% -59.56%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share $0.00 -$0.02 -$58.51K
COMMON SHARES
Basic Shares Outstanding 5.914M shares 10.01M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $210.00 $137.6K $900.6K
YoY Change -99.97% -84.72%
Cash & Equivalents $70.54K $350.8K $900.5K
Short-Term Investments
Other Short-Term Assets $65.83K $78.31K $260.9K
YoY Change -52.36% -69.98%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $165.2K $215.9K $1.161M
YoY Change -82.22% -81.41%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles $5.000M $5.000M
YoY Change 0.0%
Long-Term Investments $38.86M $80.62M $77.28M
YoY Change -49.79% 4.31%
Other Assets $70.33K $213.2K
YoY Change
Total Long-Term Assets $38.93M $80.83M $77.28M
YoY Change -49.7% 4.59%
TOTAL ASSETS
Total Short-Term Assets $165.2K $215.9K $1.161M
Total Long-Term Assets $38.93M $80.83M $77.28M
Total Assets $39.09M $81.04M $78.45M
YoY Change -50.09% 3.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.649M $2.552M $18.50K
YoY Change 2066.96% 13691.99%
Accrued Expenses $275.0K $215.8K $110.8K
YoY Change 237.89% 94.89%
Deferred Revenue
YoY Change
Short-Term Debt $2.046M $1.671M $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.652M $47.63M $345.3K
YoY Change 1226.13% 13693.93%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $2.705M $2.705M $2.705M
YoY Change 0.0% 0.0%
Total Long-Term Liabilities $2.705M $2.705M $2.705M
YoY Change 0.0% 0.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.652M $47.63M $345.3K
Total Long-Term Liabilities $2.705M $2.705M $2.705M
Total Liabilities $8.357M $50.34M $3.050M
YoY Change 166.92% 1550.38%
SHAREHOLDERS EQUITY
Retained Earnings -$7.617M -$6.921M
YoY Change 264.52%
Common Stock $228.00 $228.00
YoY Change 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$7.617M -$6.921M -$1.881M
YoY Change
Total Liabilities & Shareholders Equity $39.09M $81.04M $78.45M
YoY Change -50.09% 3.31%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income $26.53K -$230.2K -$569.3K
YoY Change -112.71% -59.56%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$42.82M $42.46M -$300.4K
YoY Change 39042.23% -14235.45%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities $42.16M $125.0K -$2.277M
YoY Change -105.49%
Cash From Investing Activities $42.16M -$125.0K -$2.277M
YoY Change -94.51%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 375.0K -$42.51M 2.277M
YoY Change -1967.12%
NET CHANGE
Cash From Operating Activities -42.82M $42.46M -300.4K
Cash From Investing Activities 42.16M -$125.0K -2.277M
Cash From Financing Activities 375.0K -$42.51M 2.277M
Net Change In Cash -280.3K -$172.3K -300.4K
YoY Change 156.19% -42.65%
FREE CASH FLOW
Cash From Operating Activities -$42.82M $42.46M -$300.4K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
usd
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
shares
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
shares
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-41183
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Welsbach Technology Metals Acquisition Corp.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
160 S Craig Place
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Lombard
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
IL
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
60148
CY2023Q1 dei City Area Code
CityAreaCode
(217)
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
615-1216
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2023Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
true
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
5913698 shares
CY2023Q1 us-gaap Cash
Cash
137596 usd
CY2022Q4 us-gaap Cash
Cash
309881 usd
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
78306 usd
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
25000 usd
CY2023Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
213182 usd
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
213182 usd
CY2023Q1 us-gaap Assets Held In Trust Current
AssetsHeldInTrustCurrent
80615246 usd
CY2022Q4 us-gaap Assets Held In Trust Current
AssetsHeldInTrustCurrent
79645156 usd
CY2023Q1 us-gaap Assets
Assets
81044330 usd
CY2022Q4 us-gaap Assets
Assets
80193219 usd
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2551519 usd
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1818627 usd
CY2023Q1 wtma Due To Affiliate
DueToAffiliate
209663 usd
CY2022Q4 wtma Due To Affiliate
DueToAffiliate
205663 usd
CY2023Q1 us-gaap Notes Payable Current
NotesPayableCurrent
215835 usd
CY2022Q4 us-gaap Notes Payable Current
NotesPayableCurrent
163384 usd
CY2023Q1 us-gaap Taxes Payable Current
TaxesPayableCurrent
347657 usd
CY2022Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
180688 usd
CY2023Q1 wtma Due To Shareholders For Redemption Of Common Stock
DueToShareholdersForRedemptionOfCommonStock
42636600 usd
CY2023Q1 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
1670537 usd
CY2022Q4 us-gaap Convertible Debt Current
ConvertibleDebtCurrent
1545537 usd
CY2023Q1 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
2704690 usd
CY2022Q4 us-gaap Deferred Compensation Liability Classified Noncurrent
DeferredCompensationLiabilityClassifiedNoncurrent
2704690 usd
CY2023Q1 us-gaap Liabilities
Liabilities
50336501 usd
CY2022Q4 us-gaap Liabilities
Liabilities
6618589 usd
CY2023Q1 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
3629722 shares
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
7727686 shares
CY2023Q1 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
10.37
CY2022Q4 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
10.29
CY2023Q1 us-gaap Temporary Equity Value Excluding Additional Paid In Capital
TemporaryEquityValueExcludingAdditionalPaidInCapital
37628336 usd
CY2022Q4 us-gaap Temporary Equity Value Excluding Additional Paid In Capital
TemporaryEquityValueExcludingAdditionalPaidInCapital
79514266 usd
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000 shares
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
100000000 shares
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2283976 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2283976 shares
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2283976 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
2283976 shares
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
228 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
228 usd
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-6920735 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-5939864 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-6920507 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-5939636 usd
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
81044330 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
80193219 usd
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
858322 usd
CY2022Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
527059 usd
CY2023Q1 us-gaap Other General Expense
OtherGeneralExpense
50000 usd
CY2022Q1 us-gaap Other General Expense
OtherGeneralExpense
50000 usd
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
908322 usd
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
577059 usd
CY2023Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
845090 usd
CY2022Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
7777 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
845090 usd
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
7777 usd
CY2023Q1 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-63232 usd
CY2022Q1 us-gaap Income Loss Attributable To Parent
IncomeLossAttributableToParent
-569282 usd
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
166969 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-230201 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-569282 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-5939636 usd
CY2023Q1 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
-750670 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-230201 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-6920507 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-1231823 usd
CY2022Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
45540 usd
CY2022Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
73142 usd
CY2022Q1 us-gaap Temporary Equity Accretion To Redemption Value Adjustment
TemporaryEquityAccretionToRedemptionValueAdjustment
-198370 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-569282 usd
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-1880793 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-230201 usd
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-569282 usd
CY2023Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
845090 usd
CY2022Q1 us-gaap Gain Loss On Investments
GainLossOnInvestments
7777 usd
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
53306 usd
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-71762 usd
CY2023Q1 us-gaap Increase Decrease In Payables To Broker Dealers
IncreaseDecreaseInPayablesToBrokerDealers
4000 usd
CY2022Q1 us-gaap Increase Decrease In Payables To Broker Dealers
IncreaseDecreaseInPayablesToBrokerDealers
136390 usd
CY2023Q1 wtma Increase Decrease In Due To Shareholders For Redemption Of Common Stock
IncreaseDecreaseInDueToShareholdersForRedemptionOfCommonStock
42636600 usd
CY2023Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
732892 usd
CY2022Q1 us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
18495 usd
CY2023Q1 us-gaap Increase Decrease In Property And Other Taxes Payable
IncreaseDecreaseInPropertyAndOtherTaxesPayable
52451 usd
CY2022Q1 us-gaap Increase Decrease In Property And Other Taxes Payable
IncreaseDecreaseInPropertyAndOtherTaxesPayable
50000 usd
CY2023Q1 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
166969 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
42464315 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-300412 usd
CY2023Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
125000 usd
CY2022Q1 us-gaap Payments For Proceeds From Other Investing Activities
PaymentsForProceedsFromOtherInvestingActivities
2276860 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-125000 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2276860 usd
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2276860 usd
CY2022Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
45540 usd
CY2022Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
45538 usd
CY2023Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
-42636600 usd
CY2023Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
125000 usd
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-42511600 usd
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2276862 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-172285 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-300410 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
523063 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1200956 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
350778 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
900546 usd
CY2023Q1 us-gaap Cash
Cash
137596 usd
CY2022Q1 us-gaap Cash
Cash
900546 usd
CY2023Q1 us-gaap Restricted Cash
RestrictedCash
213182 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
350778 usd
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Disposal Group Including Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsDisposalGroupIncludingDiscontinuedOperations
900546 usd
CY2022Q1 us-gaap Deferred Offering Costs
DeferredOfferingCosts
79690 usd
CY2022Q1 wtma Initial Value Of Class A Common Stock Subject To Possible Redemption
InitialValueOfClassACommonStockSubjectToPossibleRedemption
2276860 usd
CY2023Q1 us-gaap Other Deferred Costs Net
OtherDeferredCostsNet
750670 usd
CY2022Q1 us-gaap Other Deferred Costs Net
OtherDeferredCostsNet
198370 usd
CY2021Q4 us-gaap Sale Leaseback Transaction Gross Proceeds Financing Activities
SaleLeasebackTransactionGrossProceedsFinancingActivities
75000000 usd
CY2023Q1 us-gaap Shares Issued
SharesIssued
347500 shares
CY2023Q1 us-gaap Stock Issued During Period Shares Purchase Of Assets
StockIssuedDuringPeriodSharesPurchaseOfAssets
1125000 shares
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Percentage Of Outstanding Stock Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
0.50 pure
CY2023Q1 wtma Shares Issued Price Per Shares
SharesIssuedPricePerShares
10
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
5000001 usd
CY2023Q1 wtma Common Stock Percentage
CommonStockPercentage
0.20 pure
CY2023Q1 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
1 pure
CY2023Q1 wtma Dissolution Expenses
DissolutionExpenses
100000 usd
CY2022Q3 us-gaap Deposits
Deposits
772769 usd
CY2022Q4 us-gaap Deposits
Deposits
772769 usd
CY2023Q1 us-gaap Payments For Deposits
PaymentsForDeposits
125000 usd
CY2023Q1 us-gaap Share Price
SharePrice
10
CY2023Q1 us-gaap Deposits
Deposits
125000 usd
CY2023Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
4097964 shares
CY2023Q1 us-gaap Temporary Equity Redemption Price Per Share
TemporaryEquityRedemptionPricePerShare
10.4
CY2023Q1 us-gaap Temporary Equity Aggregate Amount Of Redemption Requirement
TemporaryEquityAggregateAmountOfRedemptionRequirement
42600000 usd
CY2022Q3 wtma Effective Incomes Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomesTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.01 pure
CY2022Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.01 pure
CY2023Q1 us-gaap Other Cost And Expense Operating
OtherCostAndExpenseOperating
137596 usd
CY2023Q1 us-gaap Restricted Cash
RestrictedCash
213182 usd
CY2023Q1 wtma Working Capital Amount
WorkingCapitalAmount
4428999 usd
CY2023Q1 wtma Financial Term
FinancialTerm
P1Y
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Use of Estimates</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">The preparation of unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires the Company’s management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements. Making estimates requires management to exercise significant judgment. Such estimates may be subject to change as more current information becomes available and accordingly the actual results could differ significantly from those estimates. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the unaudited condensed consolidated financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"> </p>
CY2022Q1 wtma Franchise Taxes
FranchiseTaxes
85232 usd
CY2021Q1 wtma Franchise Taxes
FranchiseTaxes
85232 usd
CY2023Q1 wtma Balance Amount
BalanceAmount
213182 usd
CY2022Q4 wtma Balance Amount
BalanceAmount
213182 usd
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i>Concentration of Credit Risk</i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><i> </i></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; text-indent: 0.25in">Financial instruments that potentially subject the Company to concentrations of credit risk consist of cash accounts in a financial institution, which, at times, may exceed the Federal Depository Insurance Corporation limit. As of March 31, 2023, the Company has not experienced losses on these accounts and management believes the Company is not exposed to significant risks on such account.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 14.55pt"> </p>
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
2.6406 pure
CY2022Q1 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0 pure
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2022Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21 pure
CY2023Q1 us-gaap Excess Stock Shares Issued
ExcessStockSharesIssued
4097964 shares
CY2023Q1 wtma Redemption Price Per Share
RedemptionPricePerShare
10.4
CY2023Q1 wtma Assets Held In Trust Accounts
AssetsHeldInTrustAccounts
80400000 usd
CY2023Q1 us-gaap Sale Leaseback Transaction Net Proceeds Financing Activities
SaleLeasebackTransactionNetProceedsFinancingActivities
79514266 usd
CY2022 us-gaap Sale Leaseback Transaction Net Proceeds Financing Activities
SaleLeasebackTransactionNetProceedsFinancingActivities
77276860 usd
CY2022 wtma Fair Value Of Public Rights At Issuance
FairValueOfPublicRightsAtIssuance
2627413 usd
CY2022 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
4626437 usd
CY2022Q1 us-gaap Sale Of Stock Consideration Received Per Transaction
SaleOfStockConsiderationReceivedPerTransaction
259136 usd
CY2023Q1 us-gaap Business Acquisition Preacquisition Contingency Amount Of Settlement
BusinessAcquisitionPreacquisitionContingencyAmountOfSettlement
242163 usd
CY2022Q4 us-gaap Financing Receivable Revolving
FinancingReceivableRevolving
205663 usd
CY2023Q1 wtma Working Capital Loans
WorkingCapitalLoans
1500000 usd
CY2022Q3 wtma Principal Amount Of Sponsor
PrincipalAmountOfSponsor
772769 usd
CY2023Q1 us-gaap Temporary Equity Other Changes
TemporaryEquityOtherChanges
-42636600 usd
CY2023Q1 wtma Accretion Of Carrying Value To Redemption Value
AccretionOfCarryingValueToRedemptionValue
750670 usd
CY2022 wtma Accretion Of Carrying Value To Redemption Value
AccretionOfCarryingValueToRedemptionValue
9491256 usd
CY2023Q1 wtma Redeemable Ordinary Shares Subject To Possible Redemption
RedeemableOrdinarySharesSubjectToPossibleRedemption
37628336 usd
CY2022 wtma Redeemable Ordinary Shares Subject To Possible Redemption
RedeemableOrdinarySharesSubjectToPossibleRedemption
79514266 usd
CY2023Q1 us-gaap Excess Stock Shares Issued
ExcessStockSharesIssued
4097964 shares
CY2023Q1 wtma Redemption Price Per Shares
RedemptionPricePerShares
10.4
CY2022Q1 wtma Aggregate Purchase Price
AggregatePurchasePrice
45540 usd
CY2022Q1 wtma Forfeited Shares
ForfeitedShares
224328 shares
CY2023Q1 wtma Limited Exception
LimitedException
0.50 pure
CY2022Q3 wtma Business Combination Into Additional Private Units
BusinessCombinationIntoAdditionalPrivateUnits
10 usd
CY2022Q4 wtma Principal Amount Of Sponsor
PrincipalAmountOfSponsor
772769 usd
CY2022Q4 wtma Business Combination Into Additional Private Units
BusinessCombinationIntoAdditionalPrivateUnits
10 usd
CY2023Q1 wtma Principal Amount Of Sponsor
PrincipalAmountOfSponsor
125000 usd
CY2023Q1 us-gaap Related Party Tax Expense Effect Of Change In Allocation Methodology
RelatedPartyTaxExpenseEffectOfChangeInAllocationMethodology
10 usd
CY2023Q1 wtma Post Business Combination Price Per Unit
PostBusinessCombinationPricePerUnit
10
CY2023Q1 wtma Balance Outstanding Promisorry Note
BalanceOutstandingPromisorryNote
1670537 usd
CY2022 wtma Balance Outstanding Promisorry Note
BalanceOutstandingPromisorryNote
1545537 usd
CY2021Q4 us-gaap Sponsor Fees
SponsorFees
10000 usd
CY2023Q1 us-gaap Other Expenses
OtherExpenses
30000 usd
CY2022Q1 us-gaap Other Expenses
OtherExpenses
30000 usd
CY2023Q1 wtma Underwriting Discount
UnderwritingDiscount
0.2
CY2023Q1 wtma Aggregate Underwriting Fee
AggregateUnderwritingFee
1545537 usd
CY2023Q1 wtma Additional Underwriting Payable Per Share
AdditionalUnderwritingPayablePerShare
0.35
CY2023Q1 us-gaap Other Loans Payable
OtherLoansPayable
2704690 usd
CY2023Q1 wtma Share Of Common Stock
ShareOfCommonStock
1 shares
CY2023Q1 us-gaap Common Stock Convertible Conversion Price Increase
CommonStockConvertibleConversionPriceIncrease
0.01
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Other Commitment
OtherCommitment
150000000 usd
CY2023Q1 us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
10
CY2022Q4 us-gaap Assets Held In Trust
AssetsHeldInTrust
298414 usd
CY2022Q4 us-gaap Income Taxes Paid
IncomeTaxesPaid
213182 usd
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
usd
CY2022Q1 wtma Forfeiture Of Shares By Sponsor To The Extent The Overallotment Option Was Not Exercised In Full
ForfeitureOfSharesBySponsorToTheExtentTheOverallotmentOptionWasNotExercisedInFull
usd
CY2022Q1 wtma Increase Decrease In Due To Shareholders For Redemption Of Common Stock
IncreaseDecreaseInDueToShareholdersForRedemptionOfCommonStock
usd
CY2022Q1 us-gaap Increase Decrease In Accrued Income Taxes Payable
IncreaseDecreaseInAccruedIncomeTaxesPayable
usd
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
usd
CY2023Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
usd
CY2023Q1 us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
usd
CY2022Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
usd
CY2022Q1 us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
usd
CY2022Q1 us-gaap Restricted Cash
RestrictedCash
usd
CY2023Q1 us-gaap Deferred Offering Costs
DeferredOfferingCosts
usd
CY2023Q1 wtma Initial Value Of Class A Common Stock Subject To Possible Redemption
InitialValueOfClassACommonStockSubjectToPossibleRedemption
usd
CY2023Q1 wtma Fair Value Of Public Rights At Issuance
FairValueOfPublicRightsAtIssuance
usd
CY2023Q1 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
usd
CY2022 us-gaap Temporary Equity Other Changes
TemporaryEquityOtherChanges
usd
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001866226

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
wtma-20230331_cal.xml Edgar Link unprocessable
0001213900-23-039750-index-headers.html Edgar Link pending
0001213900-23-039750-index.html Edgar Link pending
0001213900-23-039750.txt Edgar Link pending
0001213900-23-039750-xbrl.zip Edgar Link pending
f10q0323ex31-1_welsbach.htm Edgar Link pending
f10q0323ex31-2_welsbach.htm Edgar Link pending
f10q0323ex32-1_welsbach.htm Edgar Link pending
f10q0323ex32-2_welsbach.htm Edgar Link pending
f10q0323_welsbachtech.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
f10q0323_welsbachtech_htm.xml Edgar Link completed
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
wtma-20230331.xsd Edgar Link pending
wtma-20230331_def.xml Edgar Link unprocessable
wtma-20230331_lab.xml Edgar Link unprocessable
wtma-20230331_pre.xml Edgar Link unprocessable